In a study released today, researchers from a variety of institutions – including the Marshfield Clinic, whose director, Dr. Murray Brilliant, is the lead author of the study – have announced that patients who use the drug L-DOPA, commonly used for Parkinson’s Disease and other movement disorders, are “significantly less likely to develop Age-related Macular Degeneration (AMD),” and that “if they do develop AMD, it is at significantly later ages.” The study, whose co-authors include McPherson ERI members Joseph Carroll of the Medical College of Wisconsin, and Scott Hebbring of the Marshfield Clinic, is a potentially major development in the search for treatments for this common disorder. Read More
